Akman Demir, GülşenTürkoğlu, RecaiSaip, SabahattinYüceyar, NurEfendi, HüsnüTuran, Ömer FarukAğan, KadriyeTerzi, MuratBoz, CavitTuncer, AslıKoçer, BelginKasap, MithatÇalışkan, ZeynepFINE Study Grp2024-12-022024-12-022019-12-011300-0667https://doi.org/10.5152/npa.2017.20515https://europepmc.org/backend/ptpmcrender.fcgihttps://hdl.handle.net/11452/48768Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.Methods: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life.Results: Forty-two patients (62% male; mean age: 35.7 +/- 9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study 44.7 +/- 9.9) were significantly higher than those at baseline [32.0 +/- 9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drugrelated.Conclusion: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.eninfo:eu-repo/semantics/openAccessOral fingolimodIntramuscular interferonDouble-blindSafetyTherapiesEfficacyOutcomesAcetatePhase-3SwitchMultiple sclerosisFingolimodPatient satisfactionQuality of lifeScience & technologyLife sciences & biomedicineClinical neurologyNeurosciences & neurologyArticle00051020760000525325756410.5152/npa.2017.205151309-4866